Medpace (MEDP) Q4 2025 earnings review
High-Calorie Revenue, Low-Calorie Growth
Medpace reported optically stunning headline numbers—Revenue surged 32% to $708.5M and EPS rose 27%—but the quality of this growth is questionable. The beat was driven almost entirely by a 68% explosion in zero-margin 'pass-through' reimbursable costs, likely tied to late-stage metabolic studies. Core service revenue grew a modest ~12%. More concerning is the widening jaw between revenue growth (32%) and backlog growth (4.3%), implying the company is burning through its order book at an unsustainable pace (23.6% conversion rate). FY26 guidance confirms the party is ending, forecasting a sharp deceleration to ~11% revenue growth.
🐂 Bull Case
Despite the noise around pass-throughs, Net Income grew 15.5% and EPS jumped 27% to $4.67. The company continues to deliver bottom-line leverage even as margins optically compress due to mix shift.
Medpace ended the year with nearly $500M in cash after spending over $912M on share repurchases in FY25. With $821.7M remaining on the authorization, the company has significant firepower to support the stock.
🐻 Bear Case
The company reported a backlog conversion rate of 23.6%, significantly higher than the historical 18-19% range. Burning backlog this fast without commensurate bookings growth (Backlog only +4% YoY) pulls forward revenue and creates a potential 'air pocket' in future quarters.
Stripping out the volatile reimbursable costs, core Service Revenue grew only ~12% YoY, far below the headline 32%. FY26 guidance for ~11% total growth suggests management knows the pass-through tailwind is temporary.
⚖️ Verdict: 🔴
Bearish. The headline beat masks a deteriorating structural picture. When a company grows revenue 32% but backlog only 4%, it is borrowing growth from the future. The massive spike in low-quality pass-through revenue distorts the P&L and cannot be extrapolated.
Key Themes
The Pass-Through Distortion
Q4's massive revenue beat was an illusion of mix. Reimbursable out-of-pocket expenses (pass-throughs) skyrocketed 68% YoY to $321M, now accounting for 45% of total revenue (up from 35% a year ago). These revenues carry zero margin. Core Service Revenue, which drives profits, grew only ~12%. This explains the margin compression and signals that the 'growth' is lower quality.
Backlog Disconnect
A healthy CRO should see backlog growth roughly track revenue growth. Medpace has a massive disconnect: Revenue +32% vs Backlog +4.3%. The book-to-bill ratio of 1.04x indicates the company is barely replacing what it burns. Unless bookings accelerate materially, revenue growth must mathematically plummet to converge with backlog growth.
Margin Compression
EBITDA margin fell to 22.6% from 24.9% a year ago. While management attributes this to the high mix of zero-margin pass-throughs (which is mathematically accurate), it highlights the lack of operating leverage in the core business to offset this dilution. FY26 guidance implies margins remaining suppressed at ~22%.
Metabolic Franchise Tailwinds
The explosion in pass-through costs is consistent with large, late-stage global trials—likely in the metabolic/obesity space highlighted in previous quarters. While these costs dilute margins, they confirm Medpace's strong positioning in the hottest therapeutic area in biopharma.
Buyback Pause
After aggressively repurchasing $912.9M worth of stock in the first three quarters of 2025, Medpace executed zero buybacks in Q4. This pause is notable given the $821.7M remaining authorization and may signal management caution regarding valuation or cash preservation ahead of a slower 2026.
Other KPIs
Accelerating. Up 68% YoY. This single line item accounted for the majority of the revenue 'beat.' It represents costs like travel and patient stipends that are passed to clients with no markup.
Accelerating. Up from ~18% historically. This metric measures how fast the company turns backlog into revenue. A rate this high suggests 'running hot' and usually precedes a slowdown unless bookings surge.
Stable. Up 39% YoY, but the Book-to-Bill ratio of 1.04x is pedestrian. To sustain 20%+ revenue growth, Medpace typically needs a book-to-bill closer to 1.2x given the current burn rate.
Guidance
Decelerating. Implies 8.9% to 12.8% YoY growth, a sharp drop from the ~20-30% pace seen in 2H 2025. This aligns with the 'Backlog Disconnect' concern.
Decelerating. Implies ~8-14% growth. The margin implied at the midpoint is ~22.1%, suggesting no meaningful expansion from 2025 levels (22.0%) and remaining below 2024 levels (22.8%).
Decelerating. Implies ~8-13% growth. This ends the streak of outsized earnings growth relative to revenue.
Key Questions
Sustainability of Burn Rate
Backlog conversion hit a record 23.6%. Is this a 'new normal' driven by the metabolic mix, or should we model a reversion to the historical 18-19% range, which would mechanically crush revenue growth?
Pass-Through Normalization
Reimbursable costs are 45% of revenue. When do you expect this wave of high-cost metabolic work to crest, and what does the revenue growth profile look like when these zero-margin dollars roll off?
Buyback Strategy
You spent over $900M on buybacks YTD but zero in Q4. What drove the decision to pause capital returns despite having $800M+ remaining on the authorization?
Book-to-Bill Outlook
With a 1.04x book-to-bill, you are barely replenishing the backlog you are burning. Do you see a path back to 1.2x+ in 1H 2026 to support double-digit growth beyond this year?